A newly published manuscript examines the relationship between HbA1c and continuous glucose monitoring (CGM)–derived metrics in adults with cystic fibrosis–related diabetes (CFRD). This work addresses an ongoing clinical question in CFRD care, particularly in the era of widespread CGM use and modern CFTR modulator therapy. Drawing on real-world data from adults with established CFRD, the study demonstrates agreement between HbA1c and CGM-derived measures of mean glycemia, reinforcing clinical relevance of HbA1c while underscoring the added value of CGM metrics. Dr. Larson Ode from our division contributed to the manuscript, highlighting her ongoing commitment to advancing evidence-based care for people with cystic fibrosis and diabetes, and we congratulate her and the full author team on this meaningful contribution to the field.